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One Sentence Summary: We report that inhibiting injury induced senescence, which 
propagates via TGFβ signalling within the regenerative epithelium, improves liver 
regeneration.  
 
 
Abstract: Liver injury results in rapid regeneration through hepatocyte proliferation and 
hypertrophy. However, after acute severe injury, such as acetaminophen poisoning, effective 
regeneration may fail. We investigated how senescence underlies this regenerative failure. In 
human acute liver disease, and murine models, p21-dependent hepatocellular senescence was 
proportionate to disease severity and was associated with impaired regeneration. In an 
acetaminophen injury model a transcriptional signature associated with the induction of 
paracrine senescence is observed within twenty four hours, and is followed by one of 
impaired proliferation. In genetic  models of hepatocyte injury and senescence we observed 
transmission of senescence to local uninjured hepatocytes. Spread of senescence depended 
upon macrophage derived TGFβ1 ligand. In acetaminophen poisoning inhibition of TGFβ 
receptor 1 (TGFβR1) improved survival. TGFβR1 inhibition reduced senescence and 
enhanced liver regeneration even when delivered after the current therapeutic window. This 
mechanism, in which injury induced senescence impairs regeneration, is an attractive 
therapeutic target for acute liver failure. 
 
 
[Main Text: ] 
Introduction 
After moderate liver injury or resection, the liver regenerates efficiently through hepatocyte 
proliferation (1, 2). However, following severe acute liver injury (ALI) there is a failure of 
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regeneration and acute liver failure (ALF) may follow. ALF can be caused by a variety of 
insults including viruses, toxins and medical therapy, with the most common single agent in 
the Western world being acetaminophen (paracetamol) (3). There are approximately 2000 
patients affected annually in the USA. Despite its relative rarity ALF is clinically important, 
due to its high morbidity and mortality in previously healthy individuals. Outcomes in ALF 
have improved modestly with advances in supportive care (4). However, once ALF of a 
defined clinical severity is established no specific medical therapies exist, recovery is 
unlikely and unless liver transplantation occurs death usually ensues (5). Novel therapies are 
needed for the potential treatment window during this progression from ALI to the most 
severe forms of ALF.  
 
Cells may enter growth arrest in response to stress, termed senescence when permanent. 
Senescence is associated with changes in morphology, lysosomal activity including 
senescence-associated β-galactosidase (SA-βGal) expression, DNA damage response (DDR) 
related alterations in chromatin structure (e.g. γH2Ax expression) and the activation of a 
dynamic pro-inflammatory senescence-associated secretory phenotype (SASP) including 
expression of IL1α and TGFβ (6, 7). When senescence results from oncogenic stress it 
reinforces cell cycle arrest in an autocrine manner (8, 9), activates immune surveillance (10-
13) and induces paracrine senescence via the SASP (14, 15). SASP may also modulate 
fibrosis and regeneration in response to acute tissue injury (11, 16, 17). Hepatocyte 
senescence involves the induction of p53 (TRP53), p21 (WAF1) and p16 (INK4A) (18). It is 
described in both chronic diseases (19) and steatosis (20), but not in acute liver disease. 
Fibroblast senescence occurs in the dermis following acute wounding (21) and acute 
myocardial infarction (22). However, acute epithelial senescence in response to liver injury is 
not described to date. 
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Here we show that acute injury is associated with a suite of senescence markers in previously 
uninjured hepatocytes. Senescence is transmitted between hepatocytes in a feedback loop 
dependent upon TGFβ derived from macrophages. Importantly, targeting TGFβ signalling 
after injury reduces senescence development and improves both regeneration and survival.  
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Results  
Acute liver injury results in proportionate acute hepatocellular senescence  
Human liver specimens resected at the time of liver transplantation from patients with hyper-
acute fulminant hepatic failure (less than 1 week from jaundice to encephalopathy, with no 
prior liver disease) showed expression of various senescence related markers: p21 (Fig. 1A), 
DcR2, γH2Ax and SA-Gal (Fig. S1). Thus, in liver disease’s most severe form a previously 
healthy liver develops widespread markers of hepatocellular senescence within days of acute 
insult. To examine a potential relationship between disease severity and senescence induction 
we then analysed a case series of human diagnostic biopsy samples from patients with sub-
massive hepatic necrosis. Here, we observed a direct association between hepatic necrosis 
and hepatocyte senescence as well as an indirect association between necrosis and 
hepatocellular proliferation (Fig. 1B and S1). Therefore, worsening acute liver injury in 
humans results in a proportional expression of senescent markers by hepatocytes, associated 
with reduced regeneration.  
 
To investigate the functional impact of senescence in acute liver injury we examined the 
established murine models of carbon tetrachloride (CCl4) (23) and acetaminophen (24) 
induced acute liver injury. Both injury models result in expression of senescence markers 
(p21, SA-Gal and p16) by hepatocytes, demonstrating features of growth arrest (absence of 
BrdU or Ki67), DDR (γH2Ax), senescence associated heterochromatic foci (HMGA2) and 
the SASP (IL1α) (Fig. 2A-C and Figs. S2 and S3). We also observed senescence marker 
expression by hepatocytes in dietary acute liver injury models (Fig. S4). In both CCl4 and 
acetaminophen induced injury expression of senescence markers is maximal two days 
following initiation and is lost following hepatocellular recovery (Fig. 2D and Figs. S2 and 
S3). In acetaminophen injury, using unbiased transcriptomics, we confirmed a senescence 
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associated signature 24 hours following injury (Fig. 2E and Tables S1 and S2). At 48 hours 
we observed p21 expression particularly focused to hepatocytes surrounding the area of 
receding necrosis at this time of resolving injury (Fig. 2F and S3C). In acute injury-induced 
senescence the principle target population is the hepatocyte, however p21 expression by non-
parenchymal cells also occurs (Fig. S2) consistent with the previous report by Krizhanovsky 
et al. (11). 
 
To assess the necessity for p21 in the formation of injury induced senescence we performed 
acetaminophen induced injury in WT and p21KO mice (Fig. 2G). Here, we measured the 
proliferative response within the perinecrotic area, where p21 was expressed by WT 
hepatocytes. Injury was equivalent between WT and p21KO mice (Fig. S3). However, 
perinecrotic hepatocellular regeneration was increased in p21KO mice compared to WT mice 
(Fig. 2H). Furthermore, whilst a negative correlation between injury and regeneration existed 
in WT mice, a positive correlation was observed in p21KO mice animals (Fig. 2I) indicating 
that in the absence of p21 injury no longer impedes the regenerative response. Together these 
data show that hepatocytes can enter a p21-dependent senescent state following acute injury 
and that this is associated with impaired local regeneration.  
 
TGFβ-dependent senescence transmission between hepatocytes in vivo. 
Rapid entry of the liver parenchyma into senescence following injury may represent a 
precursor to cell death. However, as we observed increasing expression of senescence 
markers by hepatocytes during the time of necrosis recession, we explored the hypothesis that 
senescence may be a cellular response to local injury and senescence. We, and others, have 
shown that oncogene-induced senescence is not only cell-autonomous but also spreads via 
paracrine factors (7, 15). Furthermore transcriptomic analysis revealed a transition between a 
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signatures associated with SASP induced senescence and one of growth arrest/senescence 
during the induction of senescence following paracetamol (Fig. 3A). Thus, we studied the 
spread of senescence in two independent genetic models of senescence.  
 
Murine Double Minute 2 (Mdm2) is a key negative regulator of p53 and the p53/p21 pathway 
is central to senescence induction. We up-regulated p53 in hepatocytes by hepatocyte-specific 
deletion of Mdm2 (Mdm2Hep) via β-naphthoflavone (βNF) activation of AhCre (25). This 
resulted in hepatocellular injury as we have previously reported (26). In the Mdm2Hep model 
we observed a rapid expression of a suite of senescence markers (Fig. S5). Using a mitogen 
cocktail, HGF and T3 (27), we attempted to promote proliferation in senescent hepatocytes in 
the Mdm2Hep model; but were unable to do so, unlike in WT hepatocytes (Fig. S5). 
Therefore, these cells are in a state of functional senescence. Next, we tested p21 dependence 
of growth arrest in this model. When Mdm2 was deleted in hepatocytes of p21KO mice, we 
observed rescue of the growth arrest (Fig. S5). In summary, the Mdm2Hep model induces 
acute p21-dependent hepatocellular senescence.  
 
To examine spread of senescence we utilised reduced titration of βNF to delete Mdm2 in a 
subpopulation of hepatocytes (partial Mdm2Hep). By doing so we aimed to distinguish cell-
autonomous and non-cell-autonomous senescence induction in hepatocytes (Fig. 3B). We 
define cell-autonomous senescence as being caused through genetic manipulation in that cell 
(e.g. through Mdm2 deletion), whereas we consider cell non-cell-autonomous senescence an 
indirect response to environmental senescence and injury in a genetically un-manipulated 
cell. In Mdm2Hep, a cell-autonomous senescence was observed with activation of p21/p16 in 
association with p53 overexpression within a subgroup of the total hepatocyte population 
(Fig. 3C and Fig. S6). Non-cell-autonomous expression of p21/p16 occurred in a distinct 
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hepatocyte subpopulation in the absence of p53 overexpression. These cells had atypical 
morphology and more pronounced p21 expression than their p21+/p53+ Mdm2-deleted 
neighbours.  
 
Next, we examined a potential geographical relationship between non-cell-autonomous p21 
expression and regional p53+ hepatocytes using a further titrated genetic induction. Here, we 
observed a lower frequency of non-cell-autonomous p21 expression and geographical 
clustering of non-cell-autonomous p21 expression with p53 overexpressing hepatocytes (Fig. 
S6).  
 
We then aimed to study senescence transmission in different models dependent upon Mdm2 
deletion. To exclude any extrahepatic effects of AhCre mediated recombination (including 
the intestinal epithelium (28)), we utilised a hepatocyte-specific induction regime using an 
adeno-associated viral vector (AAV8-thyroxine binding globulin [TBG]) to induce 
hepatocyte-specific deletion of Mdm2 (29). As predicted, AAV8-TBG-Cre induced deletion 
of Mdm2 in a subpopulation of hepatocytes (Fig. S6). In this model non-cell-autonomous p21 
expression was also observed  (Fig. 3D). We did observe a very low (0.3% hepatocytes) cre-
independent expression of p21 as a result of transfection with the control AAV8 vector (Fig. 
S6). To test transmission of senescence to WT hepatocytes we utilised a large scale 
hepatocyte repopulation model. Here, using iterative βNF dosing, the livers of AhCre 
Mdm2fl/fl mice were repopulated hepatocytes derived from transplanted WT GFP-tagged cells 
(26). Following final βNF dosing and p53 expression by native hepatocytes, transplanted WT 
hepatocytes expressed p21; particularly at the margins of the engrafted nodules (Fig. 3E).  
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In the Mdm2Hep model we observed activation of the TGFβ pathway (Fig. S5). TGFβR1 was 
expressed by hepatocytes, in addition to non-epithelial cells. The TGFβR1, whilst its ligand, 
TGFβ1, was expressed both by non-parenchymal cells and to a lesser degree by hepatocytes. 
As p21 is a canonical TGFβ signalling target gene and the TGFβ signalling pathway has a 
role in oncogene-induced paracrine senescence (14, 15), we hypothesised that the TGFβ1 
ligand plays a mechanistic role in non-cell-autonomous p21 expression. To test the functional 
role of TGFβR1 and TGFβ1 ligand in transmitted senescence we utilised a model of 
hepatocyte-specific TGFβ signal pathway activation using LSL-TGFβR1-CA mice, which 
possess a genetically inducible constitutively active TGFβR1 (30). This was activated using 
hepatocyte-targeted recombination (AAV8-TBG-Cre). In this model we observed TGFβ 
pathway activation and acute senescence marker induction in hepatocytes. This was 
accompanied by liver injury and increased paracrine TGFβ1 ligand production (Fig. 3F and 
S7 and S8). Using this as a further model of senescence induction in vivo, we investigated 
non-cell-autonomous senescence driven specifically by the TGFβ pathway as a model distinct 
from Mdm2 deletion. Using lower titrations of AAV8-TBG-Cre we induced TGFβ pathway 
activation and a R26-LSL-tdTomato reporter in approximately 5% of hepatocytes. Here we 
observed evidence of non-cell-autonomous spread of senescence to adjacent hepatocytes in 
response to cell-autonomous TGFβ pathway activation (Fig. 3G). Thus, we observed non-
cell-autonomous senescence in various models of acute hepatocellular senescence in vivo; 
demonstrating that senescence can spread within the epithelium.  
 
To test the necessity of TGFβ signalling for the transmission of senescence we returned to the 
Mdm2Hep model. Using SB525334, a small molecule inhibitor of TGFβR1, in the partial 
Mdm2Hep model we observed reduced hepatocellular pSMAD3 without affects upon 
hepatocyte Mdm2Hep efficiency (Fig. S6). SB525334 in partial Mdm2Hep resulted in 
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reduced non-cell-autonomous expression of p21 (Fig. 3H), demonstrating that TGFβ 
signalling was required for the paracrine induction of non-cell-autonomous p21 in this model.  
 
Senescence induced by acute injury is dependent upon macrophage derived TGFβ. 
Clinically relevant TGFβ inhibitors are currently available (31). Given our findings of TGFβ-
dependent transmitted senescence in the genetic models, we examined the functional role of 
TGFβR1 signalling (Fig. 4A) in senescence formation in acute liver injury. In human 
fulminant liver failure, senescent hepatocytes show TGFβ pathway activity (Fig. 4B). 
Acetaminophen induced liver injury in mice is accompanied by elevated TGFβ1 ligand (Fig. 
4C and D). SMAD7 (a TGFβ pathway target gene) is expressed upon injury and up-regulated 
particularly by perinecrotic hepatocytes (Fig. 4E). These perinecrotic hepatocytes express 
both TGFβR1 and senescence markers adjacent to local TGFβ expression (Fig. 4F and Fig. 
S10). Therefore, we observed evidence of active TGFβ signalling in senescent hepatocytes 
adjacent to necrosis following acute injury.  
 
Macrophages are a known source of TGFβ ligands, particularly in the context of tissue injury 
(32). Perinecrotic macrophages in murine acetaminophen-induced liver injury express TGFβ1 
ligand (Fig. 5A). As both TGFβ and CCL2 (a macrophage chemokine and known SASP 
component) are associated with severe human acute liver disease (33), we proceeded to 
examine the functional role of macrophages recruitment and TGFβ ligand expression in 
senescence induction in the injury models. A SASP related pro-migratory chemokine axis 
develops in partial Mdm2Hep with expression of both chemokine ligands and receptors (Fig. 
S11). CCL2 is expressed by non-parenchymal cells in and around the areas of hepatocellular 
necrosis in acetaminophen injury (Fig. 5B) prior to peripheral monocytosis (Fig. 5C) and 
then local macrophage accumulation (Fig. 5D).  
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To examine the role of macrophages in non-cell-autonomous senescence we returned to the 
Mdm2Hep model. Inhibition of leukocyte recruitment via CCL2 blockade in the Mdm2Hep 
model reduced non-cell-autonomous p21 expression and improved hepatocellular 
regeneration (Fig. 5E and S11). Next we next performed macrophage ablation using 
liposomal clodronate in the partial Mdm2Hep model. This reduced hepatic TGFβ1 expression 
by 87% (Fig. 5F and S11), implying that macrophages are the principal source of the TGFβ1 
ligand. Consistent with this hypothesis both p21 gene expression and non-cell-autonomous 
p21 expression were reduced when macrophages were depleted in the Mdm2Hep model. To 
functionally test the role of macrophage derived TGFβ1 ligand in liver injury we used 
myeloid specific TGFβ1 deletion in the acetaminophen model (Fig. 5G and S11). This 
resulted in equivalent injury but improved regeneration. Therefore, macrophage-derived 
TGFβ1 ligand is required for optimal induction of paracrine senescence following acute liver 
injury.  
 
Inhibition of TGFβR1 signalling impairs senescence induction and improves regeneration 
function and outcome in acute liver injury. 
Given the finding of TGFβ-dependent paracrine senescence in the genetic models, we tested 
whether this effect was also observed in widely accepted clinically relevant models of liver 
injury - the CCL4 and acetaminophen models. We examined the effect of TGFβ signalling 
disruption in both acute and chronic CCl4 models. In the acute model we used the TGFβR1 
inhibitor AZ12601011 (AstraZeneca) administered twelve hours after administration of 1µl/g 
CCl4. (Fig. S12). This resulted in reduced senescence induction, improved regeneration and 
reduced jaundice. In a chronic model CCl4 was given repeatedly over eight weeks in 
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combination with a genetic depletion approach targeting hepatocellular TGFβR1 
(ΔTGFβR1Hep; Fig. S12). Here, we also observed reduced hepatocellular p21 expression and 
increased hepatocellular proliferation. Next, we examined ΔTGFβR1Hep in acute 
acetaminophen-induced injury (Fig. S13). Here we observed early necrosis equivalent to 
controls but reduced hepatocellular p21 expression by perinecrotic hepatocytes. There was 
also an altered distribution of hepatocellular regeneration, with marked proliferation by 
perinecrotic hepatocytes. Accelerated resolution of necrosis was observed in mice lacking 
hepatocellular TGFβR1. 
 
To test the clinical utility of TGFβR1 inhibition we administered AZ12601011 at the time of 
a lethal acetaminophen dose (Fig. 6A). TGFβR1 inhibition resulted in marked clinical 
improvement from 6-16 hours and permitted survival following 525mg/kg acetaminophen 
dosing (Fig. 6B). At endpoint, vehicle treated mice showed worsened jaundice compared to 
AZ12601011 treated counterparts (Fig. 6C).  
 
Conventional treatment of acetaminophen toxicity in humans involves N-acetylcysteine 
therapy which, to be effective, must be given within eight hours or four hours in man and 
mice respectively (34). Many patients present to medical services too late for this to be 
effective (35). In order to model delayed therapy after this limited treatment window we used 
small molecule TGFβR1 inhibition with therapeutic intent in ‘delayed presentation’ 
acetaminophen poisoning; commencing either SB525334 (Tocris) or AZ12601011 
(AstraZeneca) twelve hours after acetaminophen administration (Fig. 6D). Additionally, as 
injury peaks prior to treatment administration, this strategy was designed to test whether the 
improvements in clinical outcome were distinct from the reduced hepatocellular injury we 
observed with synchronous toxin and therapy administration. Using SB525334, downstream 
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signalling through TGFβR1 was inhibited and necrosis was unchanged (Fig. S14). Liver 
injury was improved upon TGFβR1 inhibition (Fig. S14), along with a resolution of jaundice 
(Fig. 6E). Hepatocellular senescence was reduced by TGFβR1 inhibition (Fig. 6F and Fig. 
S14) and hepatocellular proliferation increased, both overall and specifically within the 
perinecrotic area (Fig. 6G). During acetaminophen-induced injury alone an apparent inverse 
relationship between severity of hepatocellular injury and hepatocellular regeneration was 
once again observed (Fig. 6H and Fig. 2I). Therefore, severe liver injury in the mouse 
recapitulates the negative correlation between injury and regeneration observed in severe 
human disease (Fig. 1). In the mouse this relationship was reversed upon inhibition of 
TGFβR1, restoring a proportional regenerative response to injury, mimicking genetic deletion 
of p21. Using a heightened dose of acetaminophen to induce injury we tested the second 
clinical compound AZ12601011 in the ‘delayed presentation’ model. Here, jaundice was 
once again improved and associated with an inhibition of hepatocellular senescence (Fig. 6I). 
These effects were accompanied by reduced local TGFβ pathway activation in perinecrotic 
hepatocytes (Fig. S14). Therefore, inhibition of TGFβ signalling following acute liver injury 
reduces hepatocellular senescence and improves regeneration and clinical recovery from 
injury.  
 
Discussion  
In contrast to minor forms of acute liver injury, where regeneration occurs efficiently, 
increasingly severe liver injury exhibits regenerative failure and poorer prognosis (4). 
Validated clinical scoring systems predict the outcomes of patients who will survive versus 
those in whom regeneration will ultimately fail (36), suggesting a tipping-point beyond which 
recovery is unlikely. The pathophysiological mechanism underlying this remains poorly 
understood and is a barrier to therapeutic development. Our finding that senescence inhibits 
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regeneration may underpin this tipping point. This data contrasts with previous reports in 
which senescence during injury can improve regeneration and limit fibrosis (37).  
 
With these data we provide a mechanistic model whereby injury induced senescence is 
amplified by macrophage-dependent paracrine TGFβ signalling (Fig. S15). In our in vivo 
models we observe the expression of local TGFβ ligand in response to cell intrinsic TGFβR 
pathway activation. This, therefore, represents a paracrine positive feedback loop reinforcing 
and amplifying local TGFβ signalling and downstream senescence.  
 
Senescence is challenging to define and study in vivo. The Mdm2Hep model shows 
functional senescence in vivo, expression of together with a suite of senescence markers (38), 
markers of the DNA damage response and,  growth arrest and the SASP that are seen in acute 
liver injury. SimilarlyLikewise, the acetaminophen model displays senescence marker 
expression, together with the a transcriptomic signature matching match of in vivo tissue from 
the acetaminophen model to that of athen in vitro Oncogene Induced Senescence (OIS) 
model (IMR90 ER:RAS (15)). Therefore we conclude that these models demonstrate  support 
a definition of senescence in vivo. A similarly The rapid establishment of a senescence 
programme (including TGFβ, direct Notch targets and p16) has been observed in OIS models 
within 48 hours (7, 39). This  and is mirrored by our in vivo observations, and is accompanied 
by of an early inflammatory signature (e.g. TGFβ, IL6 and NFκB) within 24 hours post 
acetaminophen which evolves into one of cell cycle arrest. In our model, SASP components 
TGFβ and IL6 are expressed concurrently within 12 hours, however Hoare et al. have shown 
that they appear sequentially in senescence in vitro (7). . Theis acute injury-induced 
senescence described here-in may represent a generic response to severe tissue injury 
whereby regional regeneration is inhibited. Our study does not dissect out the mechanisms 
Formatted: Font: Italic
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which link hepatocellular injury to senescence initiation. Whether the recently described 
cGAS-STING driven senescence pathway detecting cytoplasmic chromatin (40) plays a 
central role in liver injury induced senescence remains to be studied.  Furthermore, the rapid 
resolution of senescent hepatocytes in these models justifies future investigation, as the 
mechanism of their clearance is unknown.  
 
We have recently reported in an in vivo model of hepatocyte growth arrest that 
cholangiocytes may act as facultative stem cells to derived hepatocytes (29) in which 
replacement of hepatocytes occurs over weeks to months. In comparison, resolution of injury 
and architecture in both acetaminophen and CCl4 models is complete within a week and is 
not accompanied by a ductular reaction. Future studies are required to test whether inhibition 
of senescence in chronic injury models (e.g. TGFβ inhibition) may affect regeneration from 
both the hepatocyte and facultative stem cell pools, however our data in genetic models 
suggest that when senescence formation is impaired the ductular expansion, which include 
facultative stem cells, is also impaired (Fig. S16).  
 
In the chronic setting, iterative CCl4-induced fibrosis has been associated with non-
parenchymal (myofibroblast) senescence and an impaired fibrotic response to injury (11). 
Consistent with this previous report we observed senescence marker expression by non-
parenchymal cells both in acute and chronic liver injury. However, following acute injury, the 
predominant population expressing senescence markers are hepatocytes. Our observations are 
consistent with a requirement for chronic or iterative injury in order to observe persistent 
populations of non-parenchymal cells with senescence marker expression. 
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In this study we have investigated TGFβ as a tractable target to interrupt paracrine induced 
non-cell-autonomous p21 expression by hepatocytes. However, other SASP components are 
also worth future investigation (15, 41, 42). In ALF TGFβ is produced in the injured liver 
(43). TGFβ tonically inhibits hepatocellular regeneration during health and changes both in 
TGFβ ligand and receptor sensitivity facilitate regeneration following partial hepatectomy 
(44, 45). However, TGFβ is believed to restrict hepatocellular regeneration rather than acting 
as a break during the termination phase of liver regeneration (1, 46). Trials of TGFβR1 or 
TGFβ inhibitory compounds in humans are currently underway (e.g. NCT02452008, 
NCT02581787 respectively; see also (31)). TGFβR2, by acting as a co-receptor of TGFβR1, 
may serve as a further potential target. Long term therapy using  TGFβ inhibition raises 
potential concerns such as carcinogenesis, autoimmunity or cardiac valvulopathies (47); 
however  these may prove to be less relevant for the short periods of therapy (<one week) 
required for acute liver failure; a condition in which the prognosis is otherwise grave. None 
the less a potential physiological role of TGFβ in acute injury may be to mechanically 
stabilize the local environment. We did not observe haemorrhagic transformation following 
TGFβR1 inhibition in our treated mice, therefore further studies to ensure efficacy and safety 
in humans are required.   
 
SASP components including chemokines (e.g. CCL2/CCR2 and CX3CL1/CX3CR1), which 
promote macrophage recruitment and local TGFβ expression within areas of necrosis, are 
well described in human fulminant hepatic failure (33, 48). Macrophage recruitment in injury 
shares similarities to the p21-dependent recruitment observed during hepatic oncogene-
induced senescence (40) and the clearance of early hepatocellular carcinoma (13). 
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Overall, severe acute hepatic necrosis induces the spread of senescence to remaining viable 
hepatocytes which impairs hepatocyte-mediated regeneration. This process is therapeutically 
modifiable providing the possibility of additional future therapy for patients with this 
devastating condition. 
 
Materials and Methods 
Study design 
This study was designed to examine the role of injury induced senescence in the mammalian 
liver. With consent and ethical approval, we used archival human tissue retrieved as part of 
routine clinical care. Murine in vivo models were used for mechanistic dissection and 
preclinical compound testing. The n for murine models was based on the predicted variance 
in the model and was powered to detect 0.05 significance of 30% magnitude; in the event that 
no predicted variance was inferable from previous work preliminary experiments were 
performed using n= 3. Animals were randomly assigned to experimental groups prior to 
experimental readings, no animals were excluded from analysis (two mice in Fig. 6G did not 
receive BrdU). No blinding was performed during animal experimental administration; 
vehicle controls were used and no bias was applied during husbandry or during tissue 
harvesting. Histological sections were assigned a randomized blinded code prior to 
quantification by a separate researcher and the randomization decoded at the time of final 
data analysis. 
Human tissue 
Human liver biopsies from a clinical series of cases of sub-massive hepatic necrosis (but not 
necessarily progressing to acute liver failure; n= 74; viral hepatitis n= 13, drug-induced 
hepatitis n= 21 and cryptogenic hepatitis n= 40) were assessed histologically using H&E, 
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CK19, p16 and Ki67 staining and evaluated by an expert pathologist (TR), who also 
performed cellular quantification using x400 magnification fields. Diagnoses were based on 
clinical and radiological data and confirmed by histology. Control human tissue was obtained 
from the Brain Bank, University of Edinburgh, comprising cases of sudden unexpected death. 
These cases were reviewed by a pathologist prior to their inclusion as normal control tissue. 
The use of human tissues for this study was approved by the Local Commission for Medical 
Ethics of the University of Leuven and the University of Edinburgh.  
 
Animal Models 
Animal welfare conditions have been previously described (26). Briefly, male and female 
animals were housed in a specific pathogen free environment and kept under standard 
conditions with a twelve hour day/night cycle and access to food and water ad libitum. Eight 
week old male C57BL/6J mice were purchased from Charles River UK. All animal 
experiments were carried out under procedural guidelines, severity protocols and within the 
UK with ethical permission from the Animal Welfare and Ethical Review Body (AWERB) 
and the Home Office (UK); or in CNIO Spain performed according to protocols approved 
193 by the CNIO-ISCIII Ethics Committee for Research and Animal Welfare (CEIyBA) and 
194 the Autonomous Community of Madrid. As described previously (26), AhCre+/WT mice 
were crossed with both Mdm2fl/fl and Mdm2fl/+ mice to generate AhCre+ Mdm2fl/fl and 
AhCreWT Mdm2fl/fl and AhCre+ Mdm2fl/+ controls and then subsequently crossed with p21KO 
(49) and TGFβR1fl/fl (50) animals. LysMCre mice were crossed with TGFβ1fl/fl animals. 
Litters from LysMCrehet TGFβ1fl/fl x LysMCreWT TGFβ1fl/fl crosses were used for 
experimental and control animals. Power calculations were not routinely performed, 
however, animal numbers were chosen to reflect the expected magnitude of response taking 
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into account the variability observed in previous experiments. Genotyping, BrdU 
administration and i.p. injection of β-Napthoflavone (βNF, Sigma UK) at 20-80mg/kg were 
performed as previously described (26, 51), with BrdU given two hours prior to tissue 
harvest. AAV8 recombination was performed as previously described (52). Briefly, viral 
particles (6.4x108, 2x1011 or 2.5x1011 genetic copies (GC)/mouse as specified) of 
AAV8.TBG.PI.Cre.rBG (UPenn Vector Core, Catalogue number: AV-8-PV1091) were 
injected via tail vein in 100µL PBS into male AhCreWT Mdm2fl/fl, LSL-TGFβR1-CAHom (30, 
53) or WT mice. Control male AhCreWT Mdm2fl/fl or LSL-TGFβR1-CAHom mice received 
equal AAV8.TBG.PI.Null.bGH (UPenn Vector Core, Catalogue number: AV-8-PV0148) 
injection. Cell transplantation was performed as previously described (26), AhCre Mdm2fl/fl 
recipient mice received 10mg/kg i.p. βNF 4 days prior to cell transplant of 5x10⁶ GFP 
expressing cells suspended in 200µL of PBS and injected intrasplenically after laparotomy. 
Transplanted 7-AAD-CD31-CD45-Ter119-EpCAM+CD24+CD133+ hepatic progenitor cells 
from WT mice fed the choline deficient ethionine supplemented diet were transfected using 
1µg of vector with a puromycin resistant CAG-GFP prior to transplantation. The 
transplantation control group received 200µL PBS only. Recipient mice received 
intraperitoneal injections of 20mg/kg βNF every ten days after transplantation to induce 
persistent liver injury. Mice were sacrificed and the livers were harvested twelve weeks after 
cell transplantation. HGF (250g/kg, R and D technologies) was administered via tail vein 
injection. Triodothyronine (T3, Sigma) was dissolved in solution (0.01M NaOH, 0.9M NaCl) 
at 0.4g/l. This solution was then neutralized with 2M HCl upto just prior to T3 precipitation 
and stored at -20C. T3 was administered at 4mg/kg to mice via subcutaneous injection. 
Choline Deficient Ethionine supplemented (CDE) and DDC dietary protocols were as 
previously described (54). 200µl of clodronate liposomes or control PBS were injected i.v. as 
previously described (54). TGFβR1 antagonists; SB525334 (Tocris) was given at 10mg/kg 
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twice daily in 10% polyethylene glycol, 5% DMSO, 85% saline vehicle by gavage; 
AZ12601011 (AstraZeneca) (47) was given at 50mg/kg twice daily in 0.5% HPMC / 0.1% 
Tween vehicle by gavage. Acetaminophen was prepared as previously described (8) and 
delivered at 350mg/kg or 450mg/kg by single i.p. injection of 20µl/g following a ten hour 
fast. 525mg/kg acetaminophen was administered by injection of 30µl/g. CCl4 was delivered 
by weekly i.p. injection for eight weeks at 0.75ml/kg or by single dose at 1ml/kg 1:3 in corn 
oil. CCL2 inhibitory antibody (#AF-4679-NA, R and D Systems) was administered (10µg per 
injection) daily for four days by. tail vein injection of a 100µg/ml stock diluted in PBS.  
 
Animal tissue harvesting and serum analysis 
Mice were killed by CO2 inhalation or cervical dislocation and blood harvested by cardiac 
puncture. Organs were harvested and stored in paraffin blocks following fixation in 10% 
formalin (in PBS) for 18 hours prior to embedding. Blood hematology was performed using 
an IDEXX ProCyte Dx analyzer on blood collected in EDTA. Serum analysis used 
commercial kits according to manufacturer’s instructions for Alanine transaminase (ALT; 
Alpha Laboratories Ltd, UK), microalbumin (Olympus Diagnostics Lt, UK), Aspartate 
Aminotransferase (AST) and Alkaline Phosphatase (Alk Phos; both Randox Laboratories, 
UK).  
 
Immunohistochemistry (IHC) and in situ hybridization (ISH).  
Three m thick paraffin sections were stained for BrdU, p16, HMGA2, γH2Ax, DcR2 and 
pSMAD3 (AB6326 – clone BU1/75, AB54210 – clone 2D9A12, AB52039, AB81299 – 
clone EP854(2)Y, AB108421 – clone EPR3588(2) and AB52903 – clone EP823Y 
respectively Abcam, UK), p53 (VP-P956-clone CM5, Vectorn), p21 (Clones BMK-2202, 
Santa Cruz and HUGO 291H ), Ki67 (M7249 - clone TEC-3 Dako), pSMAD2/3, pSMAD2 
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(Cell Signalling #8828 – clone D26F4, #3101 ), CYP2D6 (Generous gift from Prof R Wolfe, 
University of Dundee) and the ductular cell marker panCK (Z0622 Dako), Species isotype 
(Santa Cruz) staining controls were routinely performed. Detection was performed with DAB 
(DAKO) followed by counterstaining with Haematoxylin or alternately with Alexa 488, 555 
or 650 (A21206, A21434A21436/S32355 and A21448 respectively; Invitrogen, UK) with a 
DAPI containing Vectashield mounting media (Vector, UK). Histochemical detection of 
senescence-associated -galactosidase (SA-G) was performed as previously described (55). 
In situ mRNA hybridization was performed using RNAscope LS probes for TGFβ1, 
TGFβR1, CCL2, SMAD7 and PPIB control (407758, 406208, 469608, 429418 and 313918); 
Advanced Cell Diagnostics) as per the manufacturer’s instructions.  
 
ELISA for murine TGFβ1 ligand was performed using Mouse/Rat/Porcine/Canine TGF-beta 
1 Quantikine ELISA Kit (R and D system) according to the manufacturer’s protocol. Whole 
liver tissue samples were homogenized in RIPA-Buffer (50mM Tris, 150 mM NaCl, 1% 
Triton x-100, 0.5% Deoxycholate, 0.1% SDS) supplemented with NaF, protease- and 
phosphatase-inhibitors and cleared by centrifugation. Protein concentration was determined 
by BCA Assay (Thermo Scientific #23225). The samples were diluted at 1:4. To allow TGFβ 
activation 20ul of 1M HCL and 20ul of 1.2M NaOH/0,5M HEPES were added to each 
100ul sample. Optical density was measured using Safire II microplate reader (TECAN) at 
450 nm (reference wavelength 540nm). 
 
Microscopy and cell counting 
Images were obtained on a Zeiss Axiovert 200 microscope using a Zeiss Axiocam MRc 
camera. Cell counts were performed manually on blinded slides and consecutive non-
overlapping fields at x200 magnification. Perinecrotic hepatocytes were defined as those 
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contacting the area of necrosis. Confocal image analysis was performed using a Leica SP5 
system with the pinhole set to 1 airy unit. DAPI, Alexafluor 488 and 555 were detected using 
band paths of 415-480, 495-540 and 561-682nm for 405, 488 543nm lasers respectively. 
Serial sections were aligned manually in Adobe Photoshop CS5; images were colour 
deconvoluted using imageJ using haematoxylin/DAB settings (version 1.5). For RNAscope 
and quantification of necrosis slides were scanned on an SCN400F slide scanner (Leica, 
Milton Keynes, UK) and the files analysed using Halo v2.0 Image Analysis Software (Indica 
Labs, Corrales, NM, USA) as previously described. For perinecrotic SMAD7 quantification, 
perinecrotic and uninjured pericentral areas were manually defined by drawing a ring (200m 
radius from vein or necrosis) around ten centrilobular structures per sample. Results are 
expressed as probe copies/area for RNAscope. Necrosis was defined after validation of 
classifier definition of healthy liver, haemorrhagic necrosis and non-haemorrhagic necrosis 
with results expressed as % area necrosis. All scale bars = 50m. 
 
Real time PCR and gene expression analysis 
Total RNA was extracted from 30-50mg tissue samples previously stored in RNAlater at -
80°C, using a combination of TRIzol reagent (Invitrogen) and Qiagen RNeasy Mini system 
(Qiagen, UK) according to both manufacturers’ instructions. gDNA decontamination, reverse 
transcription and real time PCR were performed using reagents and primers (Quantifast and 
Quantitect respectively, Qiagen, UK) on an ABI Prism 7500 cycler, except for 
chemokine/chemokine receptor analysis which was performed as previously described (56). 
Data were collected using the LightCycler system following normalization to the 
housekeeping gene peptidylprolyl isomerase A (Ppia); or Gapdh for chemokine/chemokine 
receptor data. All samples were run in triplicates. 
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RNAseq analysis 
Total RNA was extracted from 30-50mg tissue samples as described above. Purified RNA 
was tested on an Agilent 2200 Tapestation using RNA screentape. Libraries for cluster 
generation and DNA sequencing were prepared following an adapted method from Fisher et 
al.(57) using Illumina TruSeq Stranded mRNA LT Kit, Quality and quantity of the DNA 
libraries was assessed on a Agilent 2200 Tapestation (D1000 screentape) and Qubit (Thermo 
Fisher Scientific) respectively. The libraries were run on the Illumina Next Seq 500 using the 
High Output 75 cycles kit (2x36cycles, paired end reads, single index). Quality checks on the 
raw RNASeq data files were done using fastqc version 0.10.1 and fastq_screen version 0.4.2. 
RNASeq reads were aligned to the GRCm38 (58) version of the mouse genome using tophat2 
version 2.1.0 (59) with Bowtie version 2.2.6.0 (60). Expression values were determined and 
statistically analysed by a combination of HTSeq version 0.5.4p3, the R 3.4.2 environment, 
utilizing packages from the Bioconductor data analysis suite and differential gene expression 
analysis based on the negative binomial distribution using the DESeq2 (61). Gene set 
enrichment analysis was performed using the Broad Institute Online Platform. An OIS 
signature was defined by the top 100 upregulated gene in the IMR90 ER:RAS model (15).  
 
Statistical analysis 
Prism software (GraphPad Software, Inc) was used for all statistical analyses; T tests were 
used from normally distributed samples (D’Agostino and Pearson omnibus test was used to 
assess Gaussian distribution) with Welch’s correction if variances differed (F test). One or 
two way ANOVA was used to compare multiple (>2) samples or groups respectively. Mean 
HPCs per x200 magnification field from 30 fields for each mouse were compared. Data are 
presented as mean +/- SEM throughout; n refers to biological replicates in all instances unless 
otherwise stated.  
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Figures:  
Fig. 1. Human liver necrosis causes acute hepatocellular senescence.  
 
(A) Explanted human livers following liver transplantation for severe acetaminophen 
overdose (n= 8) show expression of senescence marker p21 by IHC detection in residual 
hepatocytes surrounding areas of necrosis (necrosis interface =  dashed white line, CV =  
central vein and * =  area of necrosis). As control liver with normal histology was used (n= 
50). Scale bars = 50µm. (B) A cases series of human sub-massive necrosis divided into 
subgroups by extent of hepatocellular necrosis (<25% n= 8, 25-50% n= 16, 50-75% n= 22, 
>75% n= 28) and quantified for hepatocellular senescence markers by IHC (p16) and 
proliferation (Ki67); * =  p<0.05. Mean ± SEM.  
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Fig. 2. Toxin-mediated liver injury models cause p21-dependent hepatocellular 
senescence.  
 
Murine acute liver injury models treated with carbon tetrachloride (CCl4, A) or 
acetaminophen (B) result in pericentral necrosis two days post administration. IHC for 
senescence (p21) plus proliferation (BrdU) or hepatocyte (HNF4α) markers is shown. (C) 
IHC for Ki67 two days following acetaminophen shows proliferation away from but not next 
to necrosis. (D) Quantification of p21+ hepatocytes post injury; n≥3 each time point, p values 
= two way ANOVA. (E) Gene Set Enrichment Analysis (GSEA) plot showing enrichment of 
the early (24 hours) acetaminophen injury signature for oncogene induced senescence (OIS) 
signature from an IMR90 ER:RAS model. ES=enrichment score, NES=normalised 
enrichment score. (F) Perinecrotic hepatocytes were quantified for p21 expression (74.9% 
mean of total perinecrotic hepatocytes were p21+ in n= 8 mice). (G) IHC for Ki67 in p21KO 
mice two days post acetaminophen induced injury shows proliferative hepatocytes in the 
perinecrotic area. Perinecrotic hepatocytes were quantified (H) and total Ki67+ hepatocytes 
related to serum Alanine Transaminase (ALT; U/l) as a marker of liver injury (I). n= 5 vs. 8, 
20 high power fields quantified each. p value = two-tailed T test. Linear regression for WT 
and p21KO: R2 0.54 and 0.92, with slope 95% confidence intervals -0.10 to -0.0045 and 0.082 
to 0.28 and probability slope≠0 p = 0.037 and 0.010 respectively. Scale bars = 50µm. CV = 
central vein, dashed white lines = necrosis interface and * = area of necrosis.  
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Fig. 3. Non-cell-autonomous senescence in hepatocyte-specific senescence models.  
(A) GSEA plotting Normalised Enrichment Scores (NES) over time in the paracetamol 
model; unbiased top 15 rank Hallmarks are shown together with the OIS signature from 
IMR90 ER:RAS, black borders highlight p values <0.05; raw data is shown in Tables S1 and 
S2. Top and bottom panel present inflammatory and cell cycle arrest signatures. (B) Scheme 
showing the use of genetic induction of transgenes in hepatocytes to induce cell-autonomous 
senescence and assessment by a combination of markers for genetic recombination and 
senescence. Presence of senescence markers in the absence of markers of genetic 
recombination identifies non-cell-autonomous senescence. (C) p53 accumulates in a 
subpopulation of hepatocytes in the partial Mdm2Hep model. Dual IHC for p21/p53 and 
p53/p16INK4As assessed by confocal microscopy. (D) Dual IHC for p53/p21 after deletion of 
Mdm2 using AAV8-TBG-Cre (2.5x1011 GC/mouse) with confocal microscopic analysis. (E) 
Confocal analysis of dual IHC for GFP/p21 in hepatocyte transplant model 94 days post 
transplantation. AhCre+ Mdm2fl/fl recipients were given WT donor cells tagged with GFP and 
iterative doses of βNF. White dotted line =  boarder of the engrafted cells. Magnified area is 
shown in individual channels. (F) IHC for p21 following hepatocellular TGFβR1 activation 
by AAV8-TBG-Cre in LSL-TGFβR1-CA mice. (G) Dual IHC for p21/RFP analysed by 
confocal microscopy after reduced dosing of AAV8-TBG-Cre in LSL-TGFβR1-CA R26-
LSL-tdTomato mice. (H) Following partial Mdm2Hep, mice were given TGFβR1 inhibitor 
(SB525334) or vehicle control. Dual IHC for p53/p21 with confocal microscopic assessment 
and quantification of non-cell-autonomous p21 expression; p = two tailed Mann-Whitney; n 
= 6 vs. 7. Mean ± SEM. Scale bars = 50µm. Open arrow = cell-autonomous senescence, 
closed arrow = non-cell-autonomous senescence and arrowhead = unaffected. 
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Fig. 4. TGFβ signalling is activated in acetaminophen-induced hepatocellular 
senescence.  
 
(A) Scheme demonstrating TGFβ ligands binding to heterodimeric TGFβ receptors, 
activation of downstream signalling through phosphorylation of SMAD2 and SMAD3 and 
transcription of target genes (e.g. SMAD7). (B) IHC detection of p21 and pSMAD2/3 in 
healthy human liver and patients with fulminant hepatic failure (FHF) secondary to 
acetaminophen; arrows = senescent hepatocytes. (C) ISH for TGFβ1 ligand in livers of 
acetaminophen treated (350mg/kg) and untreated C57BL/6J mice. TGFβ1 ligand is expressed 
by non-parenchymal cells with a monocyte-like appearance. Scale bars = 50µm. CV = central 
vein and * =  area of necrosis. (D) ELISA of liver TGFβ1 ligand in untreated and 
acetaminophen treated mice (12 hours); n= 6 vs. 7, p value = two tailed Mann-Whitney. 
Mean ± SEM. (E) Quantification of perinecrotic SMAD7 expression by ISH (two days 
following acetaminophen); one-tailed Mann-Whitney test. (F) Liver serial sections assessed 
for SMAD7, TGFβR1 and TGFβ1 ligand and p21 by ISH and IHC respectively (twelve hours 
post acetaminophen).  
  
35 
 
Fig. 5. Macrophage recruitment and TGFβ1 production drives hepatocellular 
senescence and impairs hepatocellular regeneration. 	
 
(A) Serial liver sections assessed for hepatic TGFβ1 ligand production and F4/80+ 
macrophages by ISH and F4/80 IHC respectively (350mg/kg acetaminophen). (B) CCL2 
chemokine expression detected by ISH. (C) Dual IHC detection of F4/80+ macrophages and 
p21+ hepatocytes. (D) Peripheral monocyte quantification following acetaminophen versus 
fasted baseline (dashed line); n = 5 each time point, p value = one way ANOVA with 
Dunnett’s multiple comparison baseline vs. day one. (E) Dual IHC for p53/p21 or IHC for 
BrdU, non-cell-autonomous hepatocyte p21 expression and proliferation were quantified 
following partial Mdm2Hep and antibody mediated CCL2 inhibition; p= 0.05, Mann-
Whitney, n= 3 vs. 3 mice. (F) Liposomal clodronate depletion of macrophages three days 
following partial Mdm2Hep vs. PBS control. TGFβ ligand and p21 expression in whole liver 
by qRT-PCR; p values = T test, n= 4 mice each group. Non-cell-autonomous p21+ 
hepatocytes were quantified following dual p53/p21 IHC; p values = T test; n= 4 mice each 
group. (G) Acetaminophen 350mg/kg was administered to LysMCre+ TGFβfl/fl and 
LysMCreWT TGFβfl/fl littermates and proliferation was assessed by BrdU IHC; p value = two 
tailed T test; n= 10 vs. 8 mice. Data presented as mean ± SEM. CV = central vein, dashed 
white line = necrotic interface and * = area of necrosis. Scale bars = 50µm. 
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Fig. 6. Pharmacological inhibition TGFβR1 signaling reduces hepatocellular senescence 
and restores proportional regenerative response after acetaminophen. 	
(A) Cohorts of male C57BL/6J mice were given vehicle control or TGFβR1 inhibition 
(AZ12601011) commencing at the time of 525mg/kg acetaminophen administration and were 
closely monitored until death or humane endpoint was reached. (B) Initially the TGFβR1 
inhibitor treated animals (n = 14) were harvested when the control animals reached endpoint 
irrespective of clinical condition (total biological replicates n = 14 (AZ12601011) and 16 
(vehicle) arms; over three separate experiments). A separate survival cohort (n = 10) using 
TGFβR1 inhibition was compared to retrospective and simultaneous vehicle controls to 
examine longer term survival; p value = Gehan-Breslow-Wilcoxon test. (C) At matched 
endpoint TGFβR1 inhibitor and vehicle treated controls were compared for serum bilirubin. 
(D) Examining delayed TGFβR1 inhibition (commencing twelve hours after acetaminophen 
in male C57BL/6J mice), SB525334 or vehicle was given twice daily. (E) Serum analysis for 
bilirubin over time; p values = two way ANOVA with Bonferroni correction, n= 8 each 
group. (F) Hepatocellular p21 IHC was quantified; p= 0.049, T test, 30 fields each in n= 8 vs. 
8 mice.  (G) IHC for hepatocellular BrdU was quantified (representative images from two 
day time point shown) in both whole liver and perinecrotic hepatocytes (day two only); p 
values = T test, n= 8 vs. 6 mice. Scale bars = 50µm. (H) In individual mice, two days post 
acetaminophen, serum ALT and BrdU+ hepatocytes were compared and linear regression 
performed; R2 0.15 and 0.71, with Slope 95% confidence intervals -0.0094 to 0.0038 and 
0.0049 to 0.085 and probability slope ≠ 0 p = 0.34 and 0.036 respectively. (I) Increased non-
fatal dose acetaminophen injury (450mg/kg) was administered to male C57BL/6J mice, 
followed by treatment with AZ12601011 or vehicle control twelve hours later. Serum 
bilirubin and p21+ hepatocytes quantified by IHC; p values = two tailed T test, n=9 each 
group. Data presented as mean ± SEM.  
